Drug Treatment Program Update
|
|
- Sybil Pitts
- 5 years ago
- Views:
Transcription
1 Drug Treatment Program Update As of March 211
2 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential information to local health authorities, treating physicians and the community-at-large on an ongoing basis. The Drug Treatment Program Update is one example of the Centre s commitment. In B.C., all anti-hiv medications are distributed at no cost to eligible HIV-infected individuals through the Centre s Drug Treatment Program (DTP). The DTP Update provides an important overview of available anti-hiv drugs, common drug combinations and distribution of active DTP participants throughout the province. DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the Centre s treatment guidelines. HIV/AIDS continues to be a pressing concern in B.C. As of March 211, 5,656 persons were receiving anti-retrovirals or other anti-hiv medications from the DTP. Table of Contents HIV/AIDS drugs available through the Centre...2 Distribution of active DTP participants by health authority...3 Distribution of active DTP participants by health services delivery areas...4 DTP participants within health authorities Vancouver Coastal Health...5 Fraser Health Authority...6 Vancouver Island Health Authority...7 Active HIV/AIDS drug treatment program participants within select cities Vancouver...1 Victoria...11 Surrey...12 Kelowna...13 Prince George...14 Number of drugs percent distribution of DTP participants on ARV therapies...15 Interior Health Authority...8 Northern Health Authority...9 Drug combination distribution of DTP participants...16 Definitions
3 HIV/AIDS Drugs available through the Centre (March 211) The following HIV/AIDS Treatment Program and Special Access Program (SAP) drugs can be requested through the Centre using a drug request prescription form. All requests received will be assessed in terms of how they meet the established HIV/AIDS drug treatment guidelines. Eligible individuals will obtain, at no cost, HIV/AIDS therapies offered by the Centre s Drug Treatment Program. Antiretroviral Drugs for HIV infection Abacavir (Ziagen ) Atazanavir (Reyataz ) Atripla (Efavirenz, Emtricitabine and Tenofovir in one tablet) Combivir (Zidovudine and Lamivudine in one tablet) Darunavir (Prezista ) for extended therapy only Delavirdine (Rescriptor ) Didanosine (Videx-EC ) Efavirenz (Sustiva ) Enfuvirtide (Fuzeon ) for extended therapy only Etravirine (Intelence ) for extended therapy only Maraviroc (Celsentri ) for extended therapy only Fosamprenavir (Telzir ) Indinavir (Crixivan ) Kaletra (Lopinavir/ritonavir tablets and liquid) Kivexa (Abacavir and Lamivudine in one tablet) Lamivudine (3TC tablets and liquid) Nelfinavir (Viracept ) Nevirapine (Viramune ) Raltegravir (Isentress ) for extended therapy only Ritonavir (Norvir tablets, capsules and liquid) Saquinavir-HG (Saquinavir hard gelcaps and tablets, Invirase ) Stavudine (Zerit ) Tenofovir (Viread ) Tipranavir (Aptivus ) for extended therapy only Truvada (Emtricitabine and Tenofovir in one tablet) Trizivir (Zidovudine, Lamivudine and Abacavir in one tablet) Zidovudine (Retrovir capsules and liquid) Certain restrictions apply to these drugs please contact St. Paul s Ambulatory Pharmacy for further information. Drugs for the Indicator Diseases of AIDS covered by the program Aerosol Pentamidine (Pneumopent ) Prophylaxis for PCP Atovaquone (Mepron ) One-time treatment for PCP, treatment for unresponsive toxoplasmosis, fourth-line PCP prophylaxis Azithromycin (Zithromax ) Prophylaxis for MAC, treatment for unresponsive toxoplasmosis Ciprofloxacin For clarithromycin-resistant Mycobacterium avium infections (MAC) Clarithromycin (Biaxin ) Mycobacterium avium infections (MAC) Ethambutol (Myambutol ) Mycobacterium avium infections (MAC) G-CSF (Filgrastim, Neupogen ) Neutropenia Ganciclovir, infusion & intravitreal Cytomegalovirus (CMV ) affecting sight or organ systems Octreotide (Sandostatin ) HIV-related diarrhea Paromomycin (Humatin ) Cryptosporidium Rifabutin (Mycobutin ) Mycobacterium avium infections (MAC) Valganciclovir (Valcyte ) Cytomegalovirus (CMV ) affecting sight or organ systems Drugs available through Health Canada's Special Access Program Albendazole Microsporidium Amphotericin, suspension (Fungilin ) Azole-resistant oral candidiasis Didanosine powder for oral solution (Videx ) for children Efavirenz liquid (DMP, Sustiva ) for children Foscarnet infusion (Foscavir) Cytomegalovirus (CMV) affecting sight or organ systems Nevirapine liquid (Viramune ) for children Stavudine liquid (D4T, Zerit ) for children Program Statistics (as of March 211) Number of participants Ever enrolled 1,27 Currently on antiretrovirals 5,656 Newly enrolled in March Gender Men 84% Women 16% Health Authorities Vancouver Coastal 58% Fraser 22% Vancouver Island 11% Interior 6% Northern 3% 2
4 Distribution of active DTP participants by health authority (March 211) Total = 5,656 Northern Vancouver Coastal Interior Vancouver Island Vancouver Coastal Fraser 3
5 Distribution of active DTP participants by health services delivery areas (March 211) Northwest Northeast Total = 5, Northern Interior North Shore/ Coast Garibaldi Thompson Cariboo Shuswap North Vancouver Island Fraser North Central Vancouver Island North Shore/ Coast Garibaldi Fraser East Okanagan Kootenay Boundary East Kootenay Vancouver South Vancouver Island Richmond Fraser South Fraser East 4
6 Active DTP participants within health authorities: Vancouver Coastal Health (March 211) Total = 3,29 North Shore/ Coast Garibaldi North Shore/ Coast Garibaldi Vancouver Richmond 5
7 Active DTP participants within health authorities: Fraser Health (March 211) Total = 1, Fraser East Fraser North Fraser South 6
8 Active DTP participants within health authorities: Vancouver Island Health (March 211) Total = 629 North Vancouver Island Central Vancouver Island South Vancouver Island 7
9 Active DTP participants within health authorities: Interior Health (March 211) Total = Thompson Cariboo Shuswap East Kootenay Kootenay Boundary Okanagan 8
10 Active DTP participants within health authorities: Northern Health (March 211) Total = 153 Northwest 1 49 Northeast Northern Interior 9
11 Active DTP participants within select cities: Vancouver (March 211) Total = 2, City Centre 161 V6G V6E V7X V6B V6C V7Y Downtown 162 V6A Eastside V5L V5K V6T V6R V6K V6S Westside 164 V6N V6L V6J V6H V6Z V6M V5Y V5T V5V Midtown 165 V5W V5N V5M North East 163 V5R V6P South 166 V5X V5P V5S 1
12 Active DTP participants within select cities: Victoria (March 211) Total = V8Y V9E 1+ V9B V8Z V8X V8N V8P V9A V8T V8R V8V V8S V8W V9C 11
13 Active DTP participants within select cities: Surrey (March 211) Total = 311 V3V V3T V3R V4N 1 19 V3W V3X V3S Surrey V4A V4P V4B South Surrey/ White Rock 12
14 Active DTP participants within select cities: Kelowna (March 211) Total = V1V V1Z V1Y V1X V1P V4T V1W 13
15 Active DTP participants within select cities: Prince George (March 211) Total = V2K 1+ V2M V2L V2N 14
16 Percent Distribution of Participants on ARV Therapies by Number of Drugs (January 1996 March 211) in HIV/AIDS Percent Distribution of Participants on ARV Therapies by Number of Drugs 1 (January March 211) 6 or more drugs 5 drugs 8 4 drugs 6 % of Participants 4 2 drugs 3 drugs 2 1 drug Mar-211 Jan-211 Nov-21 Sep-21 Jul-21 May-21 Mar-21 Jan-21 Nov-29 Sep-29 Jul-29 May-29 Mar-29 Jan-29 Nov-28 Sep-28 Jul-28 May-28 Mar-28 Jan-28 Nov-27 Sep-27 Jul-27 May-27 Mar-27 Jan-27 Nov-26 Sep-26 Jul-26 May-26 Mar-26 Jan-26 Nov-25 Sep-25 Jul-25 May-25 Mar-25 Jan-25 Nov-24 Sep-24 Jul-24 May-24 Mar-24 Jan-24 Nov-23 Sep-23 Jul-23 May-23 Mar-23 Jan-23 Nov-22 Sep-22 Jul-22 May-22 Mar-22 Jan-22 Nov-21 Sep-21 Jul-21 May-21 Mar-21 Jan-21 Nov-2 Sep-2 Jul-2 May-2 Mar-2 Jan-2 Nov-1999 Sep-1999 Jul-1999 May-1999 Mar-1999 Jan-1999 Nov-1998 Sep-1998 Jul-1998 May-1998 Mar-1998 Jan-1998 Nov-1997 Sep-1997 Jul-1997 May-1997 Mar-1997 Jan-1997 Nov-1996 Sep-1996 Jul-1996 May-1996 Mar-1996 Jan-1996 Date Please refer to Disclaimer Report Date: 21-APR
17 Drug Combination: Distribution of DTP Participants (January 1999 March 211) 1 in HIV/AIDS Distribution of Participants in HIV/AIDS Drug Treatment Program by Drug Combination (January March 211) OTHER 9 8 NNRTI/no PI BOOSTED PI OR MORE PIs MDRT Mar-211 Jan-211 Nov-21 Sep-21 Jul-21 May-21 Mar-21 Jan-21 Nov-29 Sep-29 Jul-29 May-29 Mar-29 Jan-29 Nov-28 Sep-28 Jul-28 May-28 Mar-28 Jan-28 Nov-27 Sep-27 Jul-27 May-27 Mar-27 Jan-27 Nov-26 Sep-26 Jul-26 May-26 Mar-26 Jan-26 Nov-25 Sep-25 Jul-25 May-25 Mar-25 Jan-25 Nov-24 Sep-24 Jul-24 May-24 Mar-24 Jan-24 Nov-23 Sep-23 Jul-23 May-23 Mar-23 Jan-23 Nov-22 Sep-22 Jul-22 May-22 Mar-22 Jan-22 Nov-21 Sep-21 Jul-21 May-21 Mar-21 Jan-21 Nov-2 Sep-2 Jul-2 May-2 Mar-2 Jan-2 Nov-1999 Sep-1999 Jul-1999 May-1999 Mar-1999 Jan-1999 Definitions: NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor): an antiretroviral drug that binds to and disables reverse transcriptase, an enzyme that HIV needs to make copies of itself. PI (Protease Inhibitor): an antiretroviral drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles. MDRT (Multiple Drug Rescue Therapy, Mega-HAART): the use of five or more antiretroviral drugs to treat HIV, typically some or all of which have been used previously by the individual. 1 or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or two or more PIs with or without a small (less than 8mg daily) additional dose of ritonavir. Boosted PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (less than 8mg daily) additional dose of ritonavir. The addition of ritonavir inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity. NNRTI/no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs. Other: a combination therapy regimen of four or fewer antiretroviral drugs, other than MDRT, 1 or more PI, Boosted PI, NNRTI/no PI (e.g. Triple NRTI regimen). 16
18 BC Centre for Excellence in HIV/AIDS > Improve the health of British Columbians with HIV through comprehensive research and treatment programs; > Develop cost-effective research and therapeutic protocols; > Provide educational support programs to health-care professionals; > Monitor the impact of HIV/AIDS on B.C. and conduct analyses of the effectiveness of HIV-related programs. Contact information Burrard St. Vancouver, B.C. V6Z 1Y6 Tel: Fax: Physician Drug Hotline: St. Paul s Hospital Pharmacy Hotline: website: info@cfenet.ubc.ca Funding for the BC Centre for Excellence in HIV/AIDS is provided by the B.C. Ministry of Health through Pharmacare and the Provincial Health Services Authority.
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationFluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationFORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary
At a Glance: VA ADAP Formulary Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Multi Class Combination Agents Protease Inhibitors
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationHIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time
STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute
ADAP Monitoring Provider Prescribing Patterns Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute WEBINAR ETIQUETTE All questions or comments can be shared either via the
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationBHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search
BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search Search 1 :When to Initiate ART Covers Questions 1-5 including to prevent transmission Component Description Review area Objectives
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationAIDS Drug Assistance Program ADAP-Miami. NEEDS ASSESSMENT July 16, 2010
AIDS Drug Assistance Program ADAP-Miami NEEDS ASSESSMENT July 16, 2010 ADAP Clients - Gender ADAP Clients by Gender FY 09/10 April 2010 to June 2010 26% 0% Males Females 26% 0% Males Females Transgender
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 November 2010 ISENTRESS 400 mg, film-coated tablet B/60 (CIP code: 383 084-8) Applicant: MSD-CHIBRET raltegravir
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationGenotyping and Drug Resistance in Clinical Practice. Case Studies
Genotyping and Drug Resistance in Clinical Practice Case Studies 12/02 40 year old Hispanic male Dx with HIV 1995 + Hx of PCP > 1x, HepC Medication history: AZT, Crixivan, Videx EC, Sustiva, Zerit, Ziagen,
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationHuman Immunodeficiency Virus Infection A Modern Day Epidemic
Human Immunodeficiency Virus Infection A Modern Day Epidemic Frank Romanelli, PharmD, MPH, BCPS Assistant Dean and Associate Professor of Pharmacy Clinical Specialist in HIV/AIDS University of Kentucky
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code
More informationThe ART of Antiretroviral Therapy in Critically-ill Patients with HIV
The ART of Antiretroviral Therapy in Critically-ill Patients with HIV Tyler Finocchio, PharmD, BCPS PGY2 Critical Care Pharmacy Resident Avera McKennan Hospital & University Health Center February 10 th,
More informationPROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY
PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY learn about the symptoms, diagnosing and treating this relatively rare brain condition associated with aids A PUBLICATION FROM Information, Inspiration and Advocacy
More informationFLORIDA!A MEDICAID' Better Health Care for all Floridians. May
CHARLIE CRIST GOVERNOR FLORIDA!A MEDICAID' Better Health Care for all Floridians HOllY BENSON SECRETARY May 26. 2009 Policy Transmittal: HMO 09-01 Policy Transmittal: PS 09-01 RE: Year Thrcc PerFormance
More information5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
More informationHIV/AIDS Update 2007
HIV/AIDS Update 2007 Joanne J. Orrick, Pharm.D., BCPS Clinical Assistant Professor University of Florida Faculty, Florida/Caribbean AIDS Education and Training Center orricjj@ufl.edu www.faetc.org orricjj@ufl.edu
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationAddressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
More informationOB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION
OB/GYN CHART REVIEW A summary of OB/GYN clinical chart review results designed to monitor the quality of care provided by a Ryan White funded OB/GYN primary care site as part of the Atlanta EMA s quality
More informationObjectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.
Objectives Identify modes HIV transmission and methods of prevention. HIV Treatment in 2010 Lisa D. Inge, Pharm.D., BCPS, AAHIVE Assistant Director, Jacksonville Campus Clinical Assistant Professor University
More informationAdherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)
Adherence Strategies for Older Adults AIDS Community Research Initiative of America (ACRIA) June 2008 Modular Objectives By the end of the module, participants will be able to: Define adherence Be able
More informationtreatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationIndustry Request Integrase Inhibitors
Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/
More informationNON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days
NON-OCCUPATIONAL POST EXPOSURE PREVENTION when you think you were exposed to hiv within the past three days A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationP.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS
P.I. Perspective December 2008, Issue #47 Information, Inspiration and Advocacy for People Living with HIV/AIDS This issue of PI Perspective represents Project Inform s coverage of the joint 2008 ICAAC
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationAppropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
More informationOctober 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
More informationHuman Immunodeficiency Virus (HIV)
HIV INFECTION! Human Immunodeficiency Virus (HIV) Infects human cells and causes gradual loss of immune system function, and these immune alterations predispose to the opportunistic infections, neoplasms,
More informationJULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationAn Update on HIV Therapy Protease Inhibitors for Treatment Experienced Patients
Page 1 An Update on HIV Therapy Protease Inhibitors for Treatment Experienced Patients An Update on HIV Therapy Protease Inhibitors for Treatment Experienced Patients Speaker: This lecture is being co-presented
More informationSection H: Treatments
TIME THIS SECTION BEGINS RECORDED HERE TSST04H Section H: Treatments H1. Have you ever taken AZT, a protease inhibitor, or any other drugs such as those listed on this card to treat your HIV infection
More informationcontinuing education for pharmacists
continuing education for pharmacists HIV/AIDS: Overview and Resources for Pharmacists Mona T. Thompson, R.Ph., PharmD Volume XXXIII, No. 9 Dr. Mona T. Thompson has no relevant financial relationships to
More informationApproach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation
More informationPrinciples of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada
Principles of HIV Drug Resistance: Resistance to New Drug Classes Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada Why Is It Important to Understand HIV Drug Resistance? 1. Resistance
More informationHIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationAntiretroviral Pregnancy Registry
Preterm Birth, low birth weight and fetal antiretroviral exposure: Estimated gestational age and birth weight data from singleton live births, 1989 through 31 January 2009 K. Beckerman, J. Albano, M. Martinez-Tristani,
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationNew Frontiers for Treatment Strategies for HIV Care
New Frontiers for Treatment Strategies for HIV Care Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Disclosures:
More informationMidwestern Underwriting Conference 2016
UNDERWRITING HIV: THE FAIRY TALE HAS BECOME REALITY Midwestern Underwriting Conference 2016 Jean-Marc Fix, FSA, MAAA VP, R&D, Optimum Re Insurance Co. AGENDA Where are we with HIV? The risk The ideal case
More informationThe Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
More informationSculpting a Better Regimen: The ART of HIV Medications
Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationHIV epidemiology since HIV in the United States. HIV Transmission
HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationRisk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf
Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationHIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine
HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent
More informationThe New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
The New Agents: Management of Experienced Patients and Resistance Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine T.D. 45 year old man with HIV infection diagnosed in 2000 On multiple
More informationNATAPNATIONAL. HIV 102: Care & Treatment AIDS TREATMENT ADVOCACY PROJECT. Origins of HIV. Table of Contents. National AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project HIV 102: Care & Treatment Written by: Jose Castro, MD University of Miami, Miller School of Medicine, Miami, FL Editorial Contributions by: Jules Levin 580 BROADWAY,
More informationWorld AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary
World AIDS Day 2014 Year-by-Year Milestones in HIV/AIDS (Adapted from The POZ Timeline: Milestones in the HIV/AIDS Pandemic with additions compiled by Eric Brus, Director of HIV Health Promotion, AIDS
More informationRecommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationHIV Today: Examining the Latest Treatment Advances, Barriers to Care, and Pharmacists Implications
HIV Today: Examining the Latest Treatment Advances, Barriers to Care, and Pharmacists Implications Humberto R. Jimenez, PharmD, BCPS, AAHIVP Comprehensive Pharmacy Services Clinical Pharmacy Specialist
More informationHIV and AIDS An update
HIV and AIDS An update Barnet branch 24 th February 2009 Neal Marshall Specialist pharmacist HIV services Royal Free Hampstead NHS Trust Objectives To gain an insight into the epidemiology of HIV To gain
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More informationThe Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease
The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project ARV Dosing in End Stage Renal Disease 1. Jayasekara, D., Aweeka, F. T., Rodriguez, R., Kalayjian, R. C., Humphreys, M. H.,
More informationMEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP
MEDICATION RELATED ISSUES IN THE HIV PATIENT LEONARD SOWAH, MBChB, MPH, FACP Overview Evalua;on and ini;al of a HIV pa;ent with respect to medica;ons Triaging of pa;ent to determine ideal follow up plan
More informationDivision of Public Health Services Office of the Assistant Director Public Health Preparedness Services
Division of Public Health Services Office of the Assistant Director Public Health Preparedness Services 150 North 18 th Avenue, #110 JANICE K. BREWER, GOVERNOR Phoenix, AZ 85007-3233 WILL HUMBLE, DIRECTOR
More informationUnderstanding Viruses CHAPTER 38. Antiviral Agents. Understanding Viruses (cont'd) Viral Infections (cont'd) Viral Infections.
Understanding Viruses CHAPTER 38 Antiviral Agents Viral replication A virus cannot replicate on its own It must attach to and enter a host cell It then uses the host cell s energy to synthesize protein,
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More information